Sign in to view content

BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)

Michael A. Singer, MD

Video
Published 2024

Related

AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial
Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS
Updates from the Field
2020
Episode 3: 5-year Results of Argus II Retina Prosthesi with Dr. Rob Devenyi
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017
Multicenter Randomized Sham-Controlled Double-Masked Phase 2b Clinical Trial of Multi-Characteristic Opsin in Patients With Advanced Retinitis Pigmentosa
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2022

Category: Hereditary Retinal Disease & Genetics

See more